^
    almost4years
    A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. (PubMed, Cancer Immunol Immunother)
    TriMixDC-MEL id/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate. Combination of optimized autologous monocyte-derived DC-formulations warrants further investigation in combination with currently approved adjuvant therapy options.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD70 (CD70 Molecule) • CD9 (CD9 Molecule) • CSF2 (Colony stimulating factor 2) • TLR4 (Toll Like Receptor 4) • CD40LG (CD40 ligand) • STAT2 (Signal transducer and activator of transcription 2) • TPSAB1 (Tryptase Alpha/Beta 1)
    |
    TriMix-DC (ex-vivo autologous dendritic cells vaccine)
    4years
    [VIRTUAL] Step by step optimization of mRNA-electroporated dendritic cells during a phase I / II vaccine trial in stage IV cutaneous melanoma patients: an increase in survival correlates with higher immunoscore in metastases, and upregulation of PEBP1 in peripheral blood (ADO 2020)
    Our data suggests optimal maturation stimulus and delivery route of DCs, and confirm early‐on biomarkers we described earlier. This will help to maximize vaccine effects in upcoming trials against various cancers.
    Clinical
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • CD70 (CD70 Molecule) • TLR4 (Toll Like Receptor 4) • CD40LG (CD40 ligand)
    |
    Immunoscore®
    |
    TriMix-DC (ex-vivo autologous dendritic cells vaccine)
    over4years
    TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. (PubMed, J Immunother Cancer)
    TriMixDC-MEL IPI treatment results in robust CD8+ T-cell responses in a meaningful portion of stage III or IV melanoma patients, and obviously in patients with a clinical response. The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.
    Clinical • Journal
    |
    CD70 (CD70 Molecule) • CD40LG (CD40 ligand)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • TriMix-DC (ex-vivo autologous dendritic cells vaccine)